Navigation Links
Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers

se 2 Trials

Poniard anticipates initiating the Phase 2 components of the CRC and HRPC trials in the third quarter of 2007.

The Phase 2 CRC trial will include patients newly diagnosed with metastatic disease and will evaluate the safety and efficacy of picoplatin when combined with fluorouracil and leucovorin (FOLPI) and administered biweekly compared with oxaliplatin (Eloxatin(R)) at 85 mg/m2 combined with fluorouracil and leucovorin (FOLFOX). The objective of this multi-center, double-blind, randomized Phase 2 CRC trial of approximately 140 patients is to demonstrate that picoplatin is a neuropathy-sparing platinum that has an improved side effect profile compared to oxaliplatin, enabling a larger randomized Phase 3 CRC trial that has the potential to demonstrate superior safety and efficacy compared to FOLFOX.

The objective of the Phase 2 HRPC trial is to position picoplatin as the preferred platinum in combination with docetaxel plus prednisone and improve on the efficacy of docetaxel as a single agent plus prednisone. This multi- center, open-label, single-arm trial of approximately 30 patients is designed to demonstrate superior efficacy when picoplatin is administered with docetaxel plus prednisone every three weeks in the first-line setting.

About Picoplatin

Picoplatin, the Company's lead product candidate, is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. In addition to the ongoing Phase 1/2 clinical trials of intravenous picoplatin in CRC and HRPC, Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in small cell lung cancer (SCLC). On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). Poniard re
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/27/2015)... , May 27, 2015 ... has announced the addition of the  "2015 ... Market"  report to their offering.  ... comprehensive five-country report contains 500 pages, 120 ... suppliers and potential market entrants identify and ...
(Date:5/27/2015)... , May 27, 2015 Protein purification ... based on differences in their physical properties. The objective ... largest amount of functional protein with fewest contaminants. The ... grow at a CAGR of around 5% to 6% ... by increased research in the pharmaceutical and biotechnological fields, ...
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Trends And Forecasts (2014 - 2019)" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,Ultrasound is ... sound waves to look at body parts ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... ANNAPOLIS, Md., April 13, 2011 PharmAthene, Inc. (NYSE ... has completed dosing in a U.S. Phase I clinical ... being developed for the prevention and treatment of inhalational ... clinical trial was designed to evaluate single escalating doses ...
... HONOLULU, April 13, 2011 Today, GE Healthcare announced ... the impact of DaTscan™ SPECT imaging on the clinical ... or symptoms of parkinsonian syndromes (PS). The results, presented ... an important step in documenting the value of DaTscan ...
Cached Medicine Technology:PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 2PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 2GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 3GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 4GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 5GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome 6
(Date:5/27/2015)... 27, 2015 The BBB Code of ... practices that enhance customer trust and confidence in business. ... Trust, eight principles that summarize important elements of creating ... standards for business accreditation by BBB. Businesses based in ... and complete application procedures will be accredited by BBB. ...
(Date:5/27/2015)... May 27, 2015 With the launch ... more robust Network Management Module (NMM) tool, monitoring provider-network ... 21 issue of Atlantic Information Services, Inc.’s (AIS) Medicare ... NMM tool, as well as analysis from industry experts ... The changes coming to the NMM were announced at ...
(Date:5/27/2015)... Austin, TX (PRWEB) May 27, 2015 ... gas information. Topics include: Why investors should consider oil ... investors, how and why wells are drilled, industry news, ... , Carson Energy's 32 years of knowledge and experience ... and gas investment community to be able to access ...
(Date:5/27/2015)... May 27, 2015 The Case ... a partnership to provide CMSA's Career and Knowledge ... collaboration seeks to strengthen the case/care management workforce ... CKP program. The mutually beneficial agreement provides Medix, ... skills of talent in the healthcare, scientific and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Coco Libre announced ... be able to reach for Organic Coconut Water to quench ... will be available at VIP areas, artist greenrooms, corporate skyboxes ... available at area hotels and on festival shuttle buses. ... this year,” said Noa Elan, Director of Strategic Partnerships for ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2
... New Zealand Aids Foundation has welcomed a decision by Pharmac(the ... the same time, they say delays over the funding may ... medicines, to be subsidized from April 1, 2007 are Tenofovir ... to Pharmac’s medical director Dr Peter Moodie the investment would ...
... slower in children who wear a special kind of ... lenses// according to a new study published in Investigative ... found that among children with two myopic parents, myopia ... when compared to those wearing single-vision lenses (SVLs).Knowing parental ...
... by a specialist headache centre, it was observed that eight ... at work; 91 per cent blamed the ineffectiveness to headaches, ... published in the March issue of Cephalalgia. ,"Migraines ... when they are often at their most productive, so the ...
... suggests that genes responsible for generating matrix metalloproteinase 1 ... long term hip replacement surgery. ,The researchers ... of whom (162) had problems after hip replacement in ... with symptoms, 91 had early signs of 'aseptic loosening,' ...
... SAN DIEGO--(BUSINESS WIRE)--Ichor Medical Systems, whose advanced electroporation ... effectiveness// of DNA drug and vaccine delivery, has ... $900,000 by the United States Department of Defense ... Institute of Infectious Diseases (USAMRIID) in Fort Detrick, ...
... certainly be an indicator of one’s happiness. Researchers at the ... nation's overall happiness and its citizens' blood pressure problems. ... across the European countries. ,These people were asked how happy ... blood pressure) and so on. ,While Sweden, Denmark ...
Cached Medicine News:Health News:New Zealand’s Pharmac Subsidies Two More HIV Drug 2Health News:Work Absence Due to Headaches Has a Substantial Socio-economic Effect 2Health News:United States Department of Defense Selects Ichor Medical Systems to Develop Biodefense Vaccine 2
Midstream Catch Kits...
... a portable, noninvasive ultrasound instrument that measures ... use, and quickly provides accurate results. In ... the BladderScan® to obtain a precise reading ... supplies the information that caregivers need to ...
... The BladderScan® BVI 6100 is a handheld, ... It is easy to operate, so any ... accurately. To view ultrasound images from exams ... patient records and reimbursement, just log on ...
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
Medicine Products: